Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 722 | 2021 |
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics‐guided warfarin dosing: 2017 update JA Johnson, KE Caudle, L Gong, M Whirl‐Carrillo, CM Stein, SA Scott, ... Clinical Pharmacology & Therapeutics 102 (3), 397-404, 2017 | 607 | 2017 |
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study MA Perera, LH Cavallari, NA Limdi, ER Gamazon, A Konkashbaev, ... The Lancet 382 (9894), 790-796, 2013 | 305 | 2013 |
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor D Yin, Y He, MA Perera, SS Hong, C Marhefka, N Stourman, L Kirkovsky, ... Molecular pharmacology 63 (1), 211-223, 2003 | 144 | 2003 |
The Missing Association: Sequencing‐Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans MA Perera, E Gamazon, LH Cavallari, SR Patel, S Poindexter, RA Kittles, ... Clinical Pharmacology & Therapeutics 89 (3), 408-415, 2011 | 126 | 2011 |
Research directions in the clinical implementation of pharmacogenomics: an overview of US programs and projects S Volpi, CJ Bult, RL Chisholm, PA Deverka, GS Ginsburg, HJ Jacob, ... Clinical Pharmacology & Therapeutics 103 (5), 778-786, 2018 | 115 | 2018 |
African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity JP Lodolce, LE Kolodziej, L Rhee, SN Kariuki, BS Franek, NM McGreal, ... The Journal of Immunology 184 (12), 7001-7009, 2010 | 107 | 2010 |
Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor Y He, D Yin, M Perera, L Kirkovsky, N Stourman, W Li, JT Dalton, ... European journal of medicinal chemistry 37 (8), 619-634, 2002 | 93 | 2002 |
Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans W Hernandez, ER Gamazon, K Aquino-Michaels, S Patel, TJ O'Brien, ... The pharmacogenomics journal 14 (3), 223-228, 2014 | 80 | 2014 |
Role of pharmacogenomics in the management of traditional and novel oral anticoagulants LH Cavallari, J Shin, MA Perera Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31 (12 …, 2011 | 80 | 2011 |
Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic–Americans and African–Americans A Bress, SR Patel, MA Perera, RT Campbell, RA Kittles, LH Cavallari Pharmacogenomics 13 (16), 1925-1935, 2012 | 74 | 2012 |
Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans R Daneshjou, ER Gamazon, B Burkley, LH Cavallari, JA Johnson, ... Blood, The Journal of the American Society of Hematology 124 (14), 2298-2305, 2014 | 73 | 2014 |
Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? MA Perera, F Innocenti, MJ Ratain Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28 (6 …, 2008 | 73 | 2008 |
The future of warfarin pharmacogenetics in under-represented minority groups LH Cavallari, MA Perera Future cardiology 8 (4), 563-576, 2012 | 68 | 2012 |
Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebo-controlled trial MS Post, MJ Van Der Mooren, CDA Stehouwer, WM Van Baal, V Mijatovic, ... Thrombosis and haemostasis 88 (10), 605-610, 2002 | 68 | 2002 |
Immunohistochemical localization of DARPP32 in striatal projection neurons and striatal interneurons in pigeons A Reiner, M Perera, R Paullus, L Medina Journal of chemical neuroanatomy 16 (1), 17-33, 1998 | 64 | 1998 |
Novel genetic predictors of venous thromboembolism risk in African Americans W Hernandez, ER Gamazon, E Smithberger, TJ O’Brien, AF Harralson, ... Blood, The Journal of the American Society of Hematology 127 (15), 1923-1929, 2016 | 55 | 2016 |
The missing linkage: what pharmacogenetic associations are left to find in CYP3A? MA Perera Expert opinion on drug metabolism & toxicology 6 (1), 17-28, 2010 | 54 | 2010 |
Genetic factors influencing warfarin dose in Black‐African patients: a systematic review and meta‐analysis IG Asiimwe, EJ Zhang, R Osanlou, A Krause, C Dillon, G Suarez‐Kurtz, ... Clinical Pharmacology & Therapeutics 107 (6), 1420-1433, 2020 | 53 | 2020 |
Association of the GGCX (CAA) 16/17 repeat polymorphism with higher warfarin dose requirements in African Americans LH Cavallari, M Perera, M Wadelius, P Deloukas, G Taube, SR Patel, ... Pharmacogenetics and genomics 22 (2), 152-158, 2012 | 52 | 2012 |